• argenx announces positive topline Phase 3 data from ADAPT-SC study evaluating subcutaneous efgartigimod for generalized myasthenia gravis

    Tuesday March 22nd 2022

  • Confo Therapeutics doses first subjects in Phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain

    Thursday March 10th 2022

  • miDiagnostics ultra-fast COVID-19 PCR Test succeeds in Brussels Airport pilot study

    Thursday February 17th 2022

  • UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

    Friday February 4th 2022

  • Large UK study shows rapid EGFR testing with Idylla™ alongside NGS has potential to enhance lung cancer patient health outcomes

    Tuesday January 25th 2022

  • Mithra announces positive top-line results from Donesta® Phase 3 studies in menopausal women

    Friday January 14th 2022

  • Oxurion provides update on clinical pipeline progress

    Friday January 7th 2022

  • VIB research at the basis of experimental gene therapy against dementia

    Wednesday December 22nd 2021

  • Your news here?

  • UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

    Friday December 10th 2021

  • MRM Health announces first patient dosed with next generation live microbiome consortia therapeutic MH002 in Phase 1b/2a study in patients with Ulcerative Colitis

    Wednesday December 8th 2021

  • Sequana Medical announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study

    Tuesday December 7th 2021


Strategic Partners